This trial is evaluating whether ABBV-151 will improve 3 primary outcomes and 17 secondary outcomes in patients with Cancer. Measurement will happen over the course of Up to approximately 9 months after the first dose date of last participant.
This trial requires 260 total participants across 2 different treatment groups
This trial involves 2 different treatments. ABBV-151 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
As with prevalence of most diseases, the age-adjusted incidence of cancer has increased in U.S. men over the last 40 years. Incidence of colorectal cancer has increased more than any other. Incidence of breast cancer has increased faster than any other.
Cancer is not a single disease entity: it is a group of diseases that are often difficult to differentiate and that are difficult to treat. The treatment of the disease depends on many factors, and a multidisciplinary approach is essential.
The most common treatment for cancer is surgery. Radiation therapy and chemotherapy, such as the anti-cancer drug Cisplatin, are also quite common. Lastly, several of cancer's major symptoms, such as constipation and headache, are also common symptom treatments for cancer.\n
There is no evidence for this "can't cure" phenomenon. The idea has been refuted and debunked for decades but it still can fool people with its appealing words. The notion of curable cancer is also disputed here.
Abbv150 has been shown to have profound anti-tumor, angiogenesis, and anti-metastasis activities. It is also effective for the treatment of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) and glioma. Further studies are warranted to explore this new drug in other cancers, particularly breast, lung, esophageal, pancreatic, and ovarian cancers.
Most families with at least one case, a family history of breast or [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer) are multiple cases and are on the same side of the family on the same side of the family. This is interesting because most multiple cancer cases in our families are clustered in one case family. So there is always a close relationship between an individual's family cancer histories. The same relationship that is seen in most families with cancer that most of them are multiple with each other. All these families can be classified as all multiple primary cancer families that are in close relation because all of them have cancers diagnosed in multiple families or in the same family.
Median age people had cancer was 65.6 years, which is consistent with the average life expectancy and expected incidence rates, which suggests that while cancer prevalence is on the increase, its incidence is decreasing, and this can be attributed to improved early detection by cancer screening initiatives, improved disease outcomes by disease-modifying and aggressive therapies, and changes in demographics. Therefore, although cancer incidence and prevalence is on the rise, the average age at which people receive cancer remains relatively stable.
Participation was more common among patients who had a family member with cancer. Physicians who recommend clinical trials usually report good experiences (e.g., benefits in survival). Clinicians should emphasize the potential benefits of clinical trials, and consider patients' preferences, before recommending trials in clinical practice.
One of the common side effects is nausea, which occurs in 21.4%-22.4% of subjects treated on abbv-151, compared to 7.7% in the placebo group. The most common reported side effects, of any number of severity, were fatigue, abdominal pain, and headache, occurring most commonly in subjects treated with abbv-151. There were no significant changes in liver function tests or serum lipid levels.
Since there is an absence of an active site of Abbv-151, its interaction with cells is thought to be non-specific. The low-molecular-weight compounds Abbv-151 and abbv-152, may exert their chemotherapeutic action through a cascade of indirect cell damage. The presence of free radicals produced at the cellular level is the underlying mechanism for this cascade of events. Further in situ and in vivo studies can now prove these hypotheses.